The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Plaintiffs Seek Mass Tort Court for Diabetes Drug Onglyza

Posted on November 16, 2017 by Larry Bodine

Plaintiffs in 44 lawsuits pending in 24 different judicial districts have requested that the Judicial Panel on Multidistrict Litigation create a new mass tort docket in the Northern District of California for cases involving the diabetes drug Onglyza.

The motion by attorneys Timothy M. Clark and Lauren Welling of Sanders Phillips Grossman, LLC in Irvine, CA, requests that the cases against defendants Bristol-Myers Squibb and AstraZeneca be consolidated in new MDL No. 2809. The JPML meets to decide on November 30.

There are 22 MDLs pending in the Northern District spread among the 20
District Judges. National counsel for the defendants are based in San Francisco. More than half of the plaintiffs are represented by counsel from California. One of the three defendants named in these suits is based in San Francisco.

Another factor in favor of the Northern District of California is its proximity to the only other consolidated proceeding related to Onglyza and the injuries asserted here. Indeed, In re: Onglyza Product Cases, JCCP 4909 pending in front of Hon. Curtis E.A. Karnow in San Francisco.

Risk of heart failure

Onglyza (Saxagliptin) was introduced to the United States market on July 31, 2009, and Kombiglyze was introduced on November 5, 2010. The defendants developed their Onglyza drugs to market and sell them as treatments for type 2 diabetes. However, the use of Onglyza carries a significantly increased risk of causing heart failure, congestive heart failure, cardiac failure, and death from heart failure.

Type 2 diabetics have an increased risk of cardiovascular disease, which is the leading cause of morbidity and mortality in the patient population. With full knowledge of the susceptibility of type 2 diabetics to cardiovascular-related adverse events, the defendants allegedly developed Onglyza and Kombiglyze XR to market and sell them to type 2 diabetics to allegedly lower adverse complications associated with type 2 diabetes.

Saxagliptin works by inhibiting incretins, which enables the stimulation of insulin to continue longer than what naturally occurs after meals.

At no time during the development of its Saxagliptin drugs did the defendants perform adequate studies to determine if their drug, and its drastic alterations of the natural incretin hormone cycle, may cause increased risks of cardiovascular-related adverse
events.

In December 2008, the FDA issued a memorandum — entitled Final Guidance for
Industry, Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. It stated that applicants of new anti-diabetic medications for the treatment of type 2 diabetes should demonstrate their products are not associated with an unacceptable increase in cardiovascular risk.

After the defendants began selling and making substantial profits off their drugs for five years, they finally conducted a clinical trial for Saxagliptin. It found that  Saxagliptin users had a statistically significant increased risk of being hospitalized due to heart failure.

An FDA committee called on the defendants to add a heart failure warning to the drug in 2015, but no label change occurred until the FDA required a new warning to the drug label on April 5, 2016.

Posted in Blog, Mass Torts

Comments are closed.

News Categories

Read about other Top Jury Verdicts

No thumbnail available

Things to Consider When You Sue an Insurance Provider

We are all too acquainted with insurance coverage in our everyday lives. According to Investopedia, everyone should have[Read More...]
The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

The Rochester Diocese Offers a $147 Million Settlement to Sex Abuse Survivors

The Rochester Catholic Diocese is offering a $147 million settlement to sex abuse survivors. This offer comes as a federal ba[Read More...]
Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

Jury Awards $77.5 Million to an Army Veteran in a 3M Earplug Case

A jury in Pensacola, Fla., federal court on Friday ordered 3M to pay $77.5 million to a U.S. Army veteran who said he suffe[Read More...]
The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

The New Mexico Supreme Court on Thursday upheld $165 million of jury awards against FedEx in a wrongful-death lawsuit stemmin[Read More...]
Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

Weight-loss program Noom has agreed to a $56 million settlement to resolve class action claims regarding its autorenewal and [Read More...]

#LegalNews

@@TheNTLtop100

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.